What Jewim Pharmaceutical (Shandong) Co., Ltd. does

Jewim Pharmaceutical (Shandong) Co., Ltd. is a privately held Chinese pharmaceutical manufacturer founded in 1993 and headquartered in Tai'an, Shandong. It operates as both a finished-dose manufacturer and a CMO/CDMO provider, with its strongest positioning in inhalation drug delivery — Metered Dose Inhalers (MDI), Dry Powder Inhalers (DPI), Nebulizer Solutions, Nasal Sprays, and Topical Sprays — alongside oral solid dosage forms (tablets, capsules, granules), enemas, Active Pharmaceutical Ingredients (Ipratropium Bromide, Fluticasone Propionate, Mometasone Furoate Monohydrate, Amisulpride), and pharmaceutical intermediates. The company self-identifies as the largest inhalation formulation manufacturer and exporter in China, backed by a 130,000 m² multi-dosage form plant, a dedicated MDI & Spray Plant with five Swiss Pamasol automated lines producing 60 million packs annually, and a 10,000+ m² R&D center staffed by 300+ scientists under a chief scientist with 20+ years of multinational pharmaceutical R&D experience.

Name

Jewim Pharmaceutical (Shandong) Co., Ltd.

Legal name

Jewim

Website

https://jewim.com

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

11–50 employees

Short description

Privately held Chinese pharmaceutical manufacturer and CMO/CDMO specializing in inhalation drug delivery (MDI, DPI, nebulizer solutions, nasal and topical sprays), oral dosage forms, and APIs, exporting to 90+ countries with GMP certifications across 20+ jurisdictions.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH), Small-Molecule API & Intermediates CDMO (HLAGABAA)

Keywords

• Pharmaceutical manufacturing
• Inhalation drug delivery
• Contract manufacturing services
• Active pharmaceutical ingredients
• Respiratory pharmaceutical products

Headquarters

HQ city

Tai'an

HQ country

China

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Contract Manufacturing (CMO): CMO services for pharmaceutical companies requiring manufacturing of inhalation products, oral dosage forms, and other pharmaceutical preparations. The company offers flexible batch sizes and comprehensive formulation capabilities.
2. Contract Development and Manufacturing (CDMO): Full-service CDMO including intermediate raw materials, technology transfers, License In/Out arrangements, and CSO (Contract Sales Organization) services. R&D investment represents 10-15% of annual revenue.
3. API Sales: Sale of Active Pharmaceutical Ingredients including Ipratropium Bromide, Fluticasone Propionate, Mometasone Furoate Monohydrate, and Amisulpride.
4. Finished Pharmaceutical Products: Direct sale of finished dosage forms including Metered Dose Inhalers, Nasal Sprays, Nebulizer Solutions, Dry Powder Inhalers, Topical Sprays, Tablets, and Capsules.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

Core offering

Jewim Pharmaceutical is a B2B pharmaceutical manufacturer and CMO/CDMO provider that produces inhalation drug delivery products (MDI, DPI, nebulizer solutions, nasal sprays, topical sprays), oral solid dosage forms (tablets, capsules), enemas, and pharmaceutical intermediates, alongside Active Pharmaceutical Ingredients (Ipratropium Bromide, Fluticasone Propionate, Mometasone Furoate Monohydrate, Amisulpride). The company sells APIs and finished dosage forms directly to pharmaceutical companies and distributors worldwide and offers full-service CDMO including formulation development, technology transfer, License In/Out, and CSO services.

Product overview

Jewim Pharmaceutical is a high-tech pharmaceutical company integrating R&D, production, and marketing. The company operates as a CDMO/CMO provider offering contract manufacturing services across multiple dosage forms including inhalation products (Metered Dose Inhaler, Dry Powder Inhaler, Nebulizer Solution, Nasal Spray, Topical Spray), oral solid dosage forms (Tablet and Capsule), rectal preparations (Enema), and Active Pharmaceutical Ingredients (API) along with pharmaceutical intermediates. The company positions itself as the largest inhalation formulation manufacturer and exporter in China, offering both finished dosage forms and API products with global GMP certifications.

Differentiator

Problem solved

Functional benefit

Products and services

• Metered Dose Inhaler (MDI) Pressurized inhaler device that delivers a specific dose of medication as an aerosol directly into the lungs for treatment of respiratory conditions such as asthma and COPD. Manufactured for global pharmaceutical companies and distributors.
• Nasal Spray Medication delivery device that sprays medication into the nasal cavity for treatment of nasal congestion and other nasal conditions.
• Dry Powder Inhaler (DPI) Inhalation device that delivers medication in powder form directly to the lungs for treatment of asthma and COPD.
• Nebulizer Solution Liquid medication that is converted into aerosol mist by a nebulizer device for inhalation treatment of respiratory diseases.
• Topical Spray Liquid or aerosol medication applied directly to the skin for targeted treatment of skin conditions such as itching, pain, inflammation and redness.
• Tablet and Capsule Oral solid dosage forms including tablets, capsules, and granules for various therapeutic applications.
• Enema Rectal solution preparation for therapeutic cleansing or medication administration.
• Ipratropium Bromide API Anticholinergic bronchodilator Active Pharmaceutical Ingredient used to treat respiratory conditions such as COPD, bronchitis, and asthma by relaxing airway muscles.
• Fluticasone Propionate API Corticosteroid Active Pharmaceutical Ingredient used for anti-inflammatory treatment of respiratory conditions.
• Mometasone Furoate Monohydrate API Corticosteroid Active Pharmaceutical Ingredient with anti-inflammatory properties used in inhalation and topical formulations.
• Amisulpride API Atypical antipsychotic Active Pharmaceutical Ingredient used for treatment of schizophrenia and other psychiatric conditions.
• Pharmaceutical Intermediate Pharmaceutical intermediate compounds used as raw materials in the synthesis of active pharmaceutical ingredients.
• CMO/CDMO Services Full-service contract manufacturing and development services for pharmaceutical companies, including intermediate raw materials, technology transfers, License In/Out arrangements, and CSO (Contract Sales Organization) services. Covers inhalation products, oral dosage forms, and APIs with flexible production batches.

Quantifiable outcome

• Products exported to over 90 countries worldwide
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Risen-Sun API / Risen-Sun PharmacoreStrategic or Co-development Partner · 19 June 2023Risen-Sun API marketing team exhibited alongside JEWIM at CPHI 2023, introducing JEWIM's API division and paving the way for international promotion of Risen-Sun products. The companies jointly appeared at booth W1D16 at CPHI China 2025. International Business Division and Formulation Research Institute collaborate with Risen-Sun on global marketing approach and CDMO services for intermediate raw materials.
• Johnson & JohnsoncoreStrategic or Co-development PartnerJohnson & Johnson is a strategic partner whose quality system supports and recognizes JEWIM's quality management standards. This partnership validates JEWIM's pharmaceutical quality standards internationally.

Scale indicators11 records

Recent moves6 records

Emerging players

• Aurobindo Pharma: Aurobindo Pharma is an India-based pharmaceutical manufacturer with growing inhalation product portfolio and contract manufacturing services. Emerging player peer to Jewim competing in cost-sensitive emerging markets and providing a low-cost alternative for inhalation generics.
• Lupin Limited: Lupin is an India-headquartered pharmaceutical company with growing inhalation and respiratory generics business and CDMO capabilities. Emerging player peer to Jewim in inhalation therapeutics, competing in emerging markets for cost-sensitive tenders with lower-cost structure.

Direct peers

• Hovione: Hovione is a Portugal-headquartered CDMO specializing in inhalation drug delivery (MDI, DPI, nasal sprays) and API manufacturing. Direct peer to Jewim: serves the same big-pharma clients seeking contract manufacturing of inhalation products, with overlapping regulatory expertise and formulation capabilities.
• WuXi AppTec / WuXi STA: WuXi STA is a China-based CDMO offering API, intermediate, and finished dosage form manufacturing. Direct peer to Jewim as a competing Chinese CDMO serving global pharma; while WuXi's scale dwarfs Jewim, both compete for similar CMO/CDMO contracts in APIs and finished drug products.
• Kindeva Drug Delivery: Kindeva Drug Delivery (formerly 3M Drug Delivery Systems) is a U.S.-based CDMO specializing in MDI, DPI, and transdermal drug delivery. Direct peer to Jewim in inhalation CDMO, with comparable inhalation manufacturing capabilities and overlap in serving generic and branded respiratory pharma.
• Asymchem Laboratories: Asymchem is a China-headquartered CDMO offering API development and manufacturing services. Direct peer to Jewim in the China-based CDMO market with overlap in API/intermediate manufacturing and serving global pharma clients; competing for similar cost-arbitrage contracts.
• Vectura Group (now Vectura Fertin Pharma): Vectura is a UK-based inhalation drug delivery CDMO with deep expertise in MDI, DPI, and nebulizer technologies. Direct peer to Jewim in the inhalation CDMO niche, with comparable customer segments (Western pharma respiratory franchises) and overlap in formulation/IP offerings.

Broad incumbents

• Lonza Group: Lonza is a Switzerland-based global CDMO leader offering API, biologics, and drug product manufacturing. Broad incumbent peer to Jewim in CDMO space, but operates at vastly larger scale with biologics capabilities Jewim does not currently have.
• Recipharm: Recipharm is a Sweden-headquartered CDMO offering sterile fill-finish, inhalation, and oral solid dose manufacturing across multiple sites. Broad incumbent peer to Jewim with overlapping inhalation capabilities but a much wider geographic footprint and broader customer base in Europe.
• Catalent: Catalent is a U.S.-headquartered global CDMO offering inhalation, oral, sterile, and biologics services. Broad incumbent peer to Jewim: serves similar big-pharma clients but operates at much larger scale, with biologics and gene therapy capabilities Jewim does not offer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/jewimpharma
• Xx.com/jewimpharma
• Pinterestpinterest.com/jewimpharma
• YouTubeyoutube.com/embed/giAZEDjJwHw
• LinkedInlinkedin.com/company/shandong-jewim-pharmaceutical-co.-ltd.

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jewim Pharmaceutical (Shandong) Co., Ltd.